Replies to post #25727 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT sold $3.3B of COVID diagnostics in 1Q22:

https://abbott.mediaroom.com/2022-04-20-Abbott-Reports-First-Quarter-2022-Results

Full-year 2022 non-GAAP EPS guidance remains unchanged at $4.70+. This guidance includes only $1.2B of cumulative COVID-diagnostics sales for 2Q22/3Q22/4Q22, which seems like a conservative forecast.